Omnicell

Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Santa Clara, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Omnicell reports robust Q4 earnings, eyes Advanced Services growth

Omnicell's Q4 2022 earnings call highlighted a strong financial performance, cost-saving initiatives, and strategic priorities for 2023. The company aims to drive growth through Advanced Services expansion, while navigating challenges such as market conditions and regulatory impacts. By focusing on operational efficiency and prudent financial management, Omnicell positions itself for sustainable growth and profitability.

Omnicell surpasses Q1 revenue targets, eyes automation for growth

Omnicell's Q1 2023 earnings call showcased robust financial performance, strategic partnerships, and cost containment efforts. The company is well-positioned to capitalize on the growing demand for automation in healthcare.

Omnicell surpasses Q2 expectations, focuses on AI strategy growth

Omnicell's Q2 performance exceeded expectations, driven by strong revenues and margins.
The company's strategic strengths lie in customer wins, AI focus, and margin management.
Challenges include market dynamics and the need for ongoing adjustments.
Opportunities for growth include raised guidance, AI strategy development, and CMS impact.

Omnicell reports Q3 earnings, faces challenges but eyes growth opportunities

Omnicell's Q3 2023 performance reflects solid total revenues, EBITDA, and EPS, with market challenges impacting bookings and product lines. The company's strengths include customer wins, profitability, and strategic growth initiatives.
Challenges include revenue impact from reduced bookings, point-of-care revenue decline, and pipeline deal deferrals. Opportunities exist in Advanced Services growth, market expansion, and cost management strategies.
Omnicell's focus on profitability, revenue growth, and customer value delivery positions it for future success. The company's strategic actions and financial outlook indicate a proactive approach to addressing challenges and seizing opportunities.

Omnicell reports Q4 revenue decline but sees growth opportunities ahead

Omnicell's Q4 2023 performance saw revenue decline but highlighted strategic wins and a focus on operational optimization.
The company's strengths lie in customer engagement, product upgrades, and expansion into new markets.
Challenges include industry costs and regulatory hurdles, but opportunities exist in market growth and service enhancements.
Overall, Omnicell remains optimistic about future demand and revenue potential, with a conservative outlook for Q1.

Omnicell surpasses Q1 revenue targets, exits product line for value

Omnicell's Q1 2024 earnings call showcased strong performance exceeding guidance, with a focus on cost management and strategic initiatives. The company announced plans to exit an international product line to improve shareholder value. Opportunities lie in the growth of the XT Amplify program and EnlivenHealth brand, despite challenges in revenue decline and operational decisions.

Omnicell reports robust Q3 earnings, eyes growth in healthcare solutions

Omnicell's Q3 2024 performance reflects strong revenue growth and operational resilience in healthcare solutions.
The company's strategic focus on customer-centricity and innovation positions it for sustained success.
Challenges in product revenue timing and cost optimization require ongoing attention for operational efficiency.
Opportunities in expanding services and market positioning offer avenues for future growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Fort Worth, TX.

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell Reports Third Quarter 2020 Results

Omnicell Reports Third Quarter 2020 Results

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Lehigh Valley Health Network Chooses Omnicell Solutions to Enhance Clinical and Operational Outcomes and Streamline Medication Management

Lehigh Valley Health Network Chooses Omnicell Solutions to Enhance Clinical and Operational Outcomes and Streamline Medication Management

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Memorial Hospital at Gulfport Selects Omnicell Central Pharmacy Dispensing Service to Enhance Medication Safety and Dispensing

Memorial Hospital at Gulfport Selects Omnicell Central Pharmacy Dispensing Service to Enhance Medication Safety and Dispensing Efficiency

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell Launches EnlivenHealth™ to Aid Retail Pharmacies and Health Plans Improve Patient Adherence, Quality Measures, and Retention

Omnicell Launches EnlivenHealth™ to Aid Retail Pharmacies and Health Plans In Improving Patient Adherence, Quality Measures, and Retention

NEW YORK--(BUSINESS WIRE)--Headline of release should read: Blue Wolf Capital Closes on Sale of Pharmaceutical Strategies Group’s 340B Business to Omnicell (instead of: Blue Wolf Capital Closes on Sale of Pharmaceutical Strategies Group to Omnicell) The updated release reads: BLUE WOLF CAPITAL CLOSES ON SALE OF PHARMACEUTICAL STRATEGIES GROUP’S 340B BUSINESS TO OMNICELL PSG’s market-leading 340B Link business is being sold for $225 million nine years after Blue Wolf’s initial investment PSG bui

CORRECTING and REPLACING Blue Wolf Capital Closes on Sale of Pharmaceutical Strategies Group’s 340B Business to Omnicell

NEW YORK--(BUSINESS WIRE)--Today, Blue Wolf Capital Partners (“Blue Wolf”), a New York-based private equity firm, announced the completion of the sale of Pharmaceutical Strategies Group’s 340B business (“PSG”) to Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies. PSG’s 340B Link business is being acquired for $225 million, and the sale marks the exit of Blue Wolf’s last portfolio company in Blue Wolf Capital

Blue Wolf Capital Closes on Sale of Pharmaceutical Strategies Group to Omnicell

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell Completes Acquisition of Pharmaceutical Strategy Group’s Leading 340B Software-Enabled Service Business

Omnicell Completes Acquisition of Pharmaceutical Strategy Group’s Leading 340B Software-Enabled Service Business

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell to Release Third Quarter 2020 Earnings Results on October 27, 2020

Omnicell to Release Third Quarter 2020 Earnings Results on October 27, 2020

The company hasn't yet set the price, interest rate, or other key terms for the securities.

Omnicell Floating $500 Million Convertible Notes Issue

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell Announces Proposed Private Placement of $500 Million of Convertible Senior Notes

Omnicell Announces Proposed Private Placement of $500 Million of Convertible Senior Notes

Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock?

Omnicell (OMCL) Down 7.7% Since Last Earnings Report: Can It Rebound?

Omnicell (OMCL) is currently witnessing slowdown in purchasing decisions by hospitals.

Omnicell (OMCL) Hurt by Coronavirus-Led Lower Product Booking

Omnicell (OMCL) expands pharmacy supply chain capabilities for better management of 340B programs through the buyout of PSG's 340B Link business.

Omnicell, Pharmaceutical Strategies Enter Acquisition Deal

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Peninsula Regional Medical Center Extends Partnership with Omnicell to Enhance Safety and Efficiency in Sterile Compounding

Peninsula Regional Medical Center Extends Partnership With Omnicell to Enhance Safety and Efficiency in Sterile Compounding

Block

In today’s article we look at recent news and updates for 3 stocks that my firm has an investment in. Again, I have a personal stake in these companies.

3 Tech Stocks For Now and Beyond (Update): SQ, FB, OMCL

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell to Acquire Pharmaceutical Strategy Group’s Leading 340B Software-Enabled Service Business

Omnicell to Acquire Pharmaceutical Strategy Group’s Leading 340B Software-Enabled Service Business

Omnicell's (OMCL) second-quarter revenues suffered due to slowdown in hospital purchasing decisions and product bookings owing to pandemic-led business disruptions.

Omnicell (OMCL) Q2 Earnings Lag Estimates, Margins Down

Omnicell, Inc. (OMCL) CEO Randall Lipps on Q2 2020 Results - Earnings Call Transcript

Omnicell (OMCL) delivered earnings and revenue surprises of -13.95% and 0.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Omnicell (OMCL) Q2 Earnings Lag Estimates

Shares of Omnicell (NASDAQ:OMCL) rose 1.8% in after-market trading after the company reported Q2 results.

Omnicell: Q2 Earnings Insights

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell Reports Second Quarter 2020 Results

Omnicell Reports Second Quarter 2020 Results

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell to Release Second Quarter 2020 Earnings Results on July 28, 2020

Omnicell to Release Second Quarter 2020 Earnings Results on July 28, 2020

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell Streamlines Pharmacy Supply Chain Through New Cloud-Based Predictive Intelligence Solution, Omnicell One

Omnicell Streamlines Pharmacy Supply Chain Through Cloud-Based Predictive Intelligence Solution

DUBLIN, July 16, 2020 /PRNewswire/ -- The "Adherence Packaging - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering. The Global Adherence Packaging market accounted for $825.13 million in 2019 and is expected to reach $1,584.75 million by 2027.

Global Adherence Packaging Market Outlook (2019 to 2027) - Featuring Omnicell, Parata Systems & RxSafe Among Others

HMS Hlds

HMSY vs. OMCL: Which Stock Is the Better Value Option?

News for Omnicell Stock (OMCL)